Cepheid Recalls Blood Culture MRSA Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid is recalling its blood culture-based MRSA test after some researchers reported getting inconclusive results, but investment analysts called the suspension of sales of the test "immaterial."

The Sunnyvale, Calif.-based molecular diagnostics firm sent a letter to customers this week saying it was suspending the sale of its Xpert MRSA/SA BC test after some researchers reported abnormally high invalid rates causing them to re-run the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."